AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
Key PointsInfrequent in CMML, AML-like mutations (CEBPA, FLT3, or NPM1) detect poor-prognosis CMML.
Key PointsInfrequent in CMML, AML-like mutations (CEBPA, FLT3, or NPM1) detect poor-prognosis CMML.
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Multiregion-sampled pancreatic cancers representing the full spectrum of clinical presentations reveal distinct genetic differences in pancreatic cancers with indolent features versus those with aggressive metastatic…
Xenia Parisi, Sanam Loghavi; Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype. Blood 2025; 145 (7): 784.…
Key PointsAmong patients alive without relapse at day +100, MRD is uncommon but identifies those at increased risk of relapse and worse survival.Most patie
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Xenia Parisi, Sanam Loghavi; Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype. Blood 2025; 145 (7): 784.…
Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young adult men. Progress in the management of GCT has been…
Key Points. First-line axi-cel demonstrated an 86% complete response rate and 3-year PFS rate of 75% in efficacy-evaluable patients with high-risk LBCLNew
Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.